California startup Protuoso raises $9.5m for “mix-and-match” drug platform - Pharmaceutical Technology

The US biotech’s technology integrates multiple protein modalities to simultaneously target a variety of disease mechanisms.

Founded by Willie Xiang and Tim Lu in California, the biotech is developing multifunctional biologics using what it calls MUXBODIES. Credit: Protuoso Bio via BusinessWire.

Protuoso Biosciences has secured $9.5m in seed financing to develop its platform which combines multiple therapeutic modalities to target diseases through several pathways simultaneously.

Founded by Willie Xiang and Tim Lu in California, the biotech is developing multifunctional biologics using what it calls MUXBODIES – recombinant fusion proteins designed to integrate a wide range of modalities. Protuoso states it can combine antibodies, cytokines, peptides, and other signalling modules into a single therapeutic. Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.